- Email: [email protected]
5194254 Enhancement of antigen immunogenicity
214
PATENT ABSTRACTS
A human IgG1 type monoclonal antibody which possesses a molecular weight in the range of 180,000+/-20,000 as measured by the method of polyacrylamide gel electrophoresis performed in the presence of sodium dodecyl sulfate and is specific to nicotinic acetylcholine receptor. The human IgGl type monoclonal antibody mentioned above is produced by a method which comprises fusing human cells capable of producing an antibody against nicotinic acetylcholine receptor with propagable human cells thereby giving rise to a hybridoma capable of producing the aforementioned human IgG1 type monoclonal antibody, selecting the hybridoma from the production of the fusion, culturing the hybridoma thereby giving rise to the aforementioned human IgG1 type monoclonal antibody, and selecting the antibody from the cultured medium. The hybridoma mentioned above is also identified.
5192694 ANTI-PCI MONOCLONAL ANTIBODY Hiroshi Nakao, Takao Nagoya, Yushi Saino, Montreal, assigned to Kowa Co Ltd A monoclonal antibody specific to a human placenta-derived coagulation inhibitor is disclosed. The antibody is produced by culturing a hybridoma which secretes it. A human placentaderived coagulation inhibitor can be purified by using the monoclonal antibody as an immunoadsorbent. The human placenta-derived coagulation inhibitor can be immunologlcally assayed by using the monoclonal antibodies.
called antigen presenting cells. The monoclonal antibody acts as a vector or delivery vehicle for targeting foreign antigens onto such recipient cells. This targeting facilitates subsequent antigen recognition by helper T-cells, which are pivotal in helping the induction of antigenspecific IgG responses.
5194370 PROMOTER LIGATION ACTIVATED TRANSCRIPTION AMPLIFICATION OF NUCLEIC ACID SEQUENCES Mark S Berninger, David M Schuster, Ayoub Rashtchian, Mississauga, assigned to Life Technologies Inc This invention discloses a scheme for producing nucleic acid end products that are functionally or exactly identical to the starting products, thereby resulting in exponential amplification of a desired nucleic acid sequence. Specifically, sequences are cycled between RNA and DNA forms using the following basic steps: (1) a T7 RNA polymerase promoter is ligated onto a single-stranded DNA template; (2) T7 RNA polymerase makes many copies of RNA: (3) a complementary DNA is made from the RNA by extension of a primer by reverse transcriptase; and (4) the RNA template is removed by ribonuclease H. This amplification method is useful for purposes such as genetic research and diagnostic assays.
5194254 ENHANCEMENT OF ANTIGEN IMMUNOGENICITY Brian H Barber, George Carayannotis, Mississauga, Canada assigned to Connaught Laboratories Limited A new method is described for eliciting IgG antibody response to proteins or synthetic peptides, particularly those that are weakly immunogenic, without the requirement for the use of adjuvants, thereby making it easier and safer to confer protection against pathogenic organisms. The antigen is coupled to a monoclonal antibody, specific for membrane determinants expressed on certain types of mammalian recipient cells,
5194371 PRODUCTION OF PRADIMICIN ANTIBIOTICS Tamotsu Furumai, Masami Hatori, Masatoshi Kakushima, Chiharu Ikeda, Kyoichiro Saitoh, Seikichi Kobaru, Mississauga, assigned to Bristol-Myers Squibb Company The present invention relates to a fermentation process for producing BMY-28960 and desxylosyl BMY-28960, and to a novel BMY-28960producing organism belonging to the genus Actinomadura and designated as strain AB 1236 (ATCC 55208).
PATENT ABSTRACTS
A human IgG1 type monoclonal antibody which possesses a molecular weight in the range of 180,000+/-20,000 as measured by the method of polyacrylamide gel electrophoresis performed in the presence of sodium dodecyl sulfate and is specific to nicotinic acetylcholine receptor. The human IgGl type monoclonal antibody mentioned above is produced by a method which comprises fusing human cells capable of producing an antibody against nicotinic acetylcholine receptor with propagable human cells thereby giving rise to a hybridoma capable of producing the aforementioned human IgG1 type monoclonal antibody, selecting the hybridoma from the production of the fusion, culturing the hybridoma thereby giving rise to the aforementioned human IgG1 type monoclonal antibody, and selecting the antibody from the cultured medium. The hybridoma mentioned above is also identified.
5192694 ANTI-PCI MONOCLONAL ANTIBODY Hiroshi Nakao, Takao Nagoya, Yushi Saino, Montreal, assigned to Kowa Co Ltd A monoclonal antibody specific to a human placenta-derived coagulation inhibitor is disclosed. The antibody is produced by culturing a hybridoma which secretes it. A human placentaderived coagulation inhibitor can be purified by using the monoclonal antibody as an immunoadsorbent. The human placenta-derived coagulation inhibitor can be immunologlcally assayed by using the monoclonal antibodies.
called antigen presenting cells. The monoclonal antibody acts as a vector or delivery vehicle for targeting foreign antigens onto such recipient cells. This targeting facilitates subsequent antigen recognition by helper T-cells, which are pivotal in helping the induction of antigenspecific IgG responses.
5194370 PROMOTER LIGATION ACTIVATED TRANSCRIPTION AMPLIFICATION OF NUCLEIC ACID SEQUENCES Mark S Berninger, David M Schuster, Ayoub Rashtchian, Mississauga, assigned to Life Technologies Inc This invention discloses a scheme for producing nucleic acid end products that are functionally or exactly identical to the starting products, thereby resulting in exponential amplification of a desired nucleic acid sequence. Specifically, sequences are cycled between RNA and DNA forms using the following basic steps: (1) a T7 RNA polymerase promoter is ligated onto a single-stranded DNA template; (2) T7 RNA polymerase makes many copies of RNA: (3) a complementary DNA is made from the RNA by extension of a primer by reverse transcriptase; and (4) the RNA template is removed by ribonuclease H. This amplification method is useful for purposes such as genetic research and diagnostic assays.
5194254 ENHANCEMENT OF ANTIGEN IMMUNOGENICITY Brian H Barber, George Carayannotis, Mississauga, Canada assigned to Connaught Laboratories Limited A new method is described for eliciting IgG antibody response to proteins or synthetic peptides, particularly those that are weakly immunogenic, without the requirement for the use of adjuvants, thereby making it easier and safer to confer protection against pathogenic organisms. The antigen is coupled to a monoclonal antibody, specific for membrane determinants expressed on certain types of mammalian recipient cells,
5194371 PRODUCTION OF PRADIMICIN ANTIBIOTICS Tamotsu Furumai, Masami Hatori, Masatoshi Kakushima, Chiharu Ikeda, Kyoichiro Saitoh, Seikichi Kobaru, Mississauga, assigned to Bristol-Myers Squibb Company The present invention relates to a fermentation process for producing BMY-28960 and desxylosyl BMY-28960, and to a novel BMY-28960producing organism belonging to the genus Actinomadura and designated as strain AB 1236 (ATCC 55208).